The TRIPS Flexibility Clause That Could Undercut Your Emerging-Market Pricing Strategy Overnight
On February 9, 2026, Brazil’s Chamber of Deputies voted 337 to 19 to fast-track a bill declaring tirzepatide, the active
Stop Assuming SPC Terms Mirror US Patent Term Extension: The Math Differs by Country
A Supplementary Protection Certificate in Germany and a Patent Term Extension in the United States both advertise the same headline
Stop Assuming SPC Terms Mirror US Patent Term Extension: The Math Differs by Country Read Post »
The Parallel Import Loophole That Undercuts Your Carefully Timed Global Launch Sequence
The Short Answer A patent does not stop a parallel importer. Once a manufacturer sells a genuine, patented drug anywhere
The Parallel Import Loophole That Undercuts Your Carefully Timed Global Launch Sequence Read Post »
The China Patent Linkage System Changed in Ways Most US IP Teams Haven’t Noticed
By the end of 2025, China’s National Intellectual Property Administration had accepted roughly 270 administrative patent linkage cases, and the
The China Patent Linkage System Changed in Ways Most US IP Teams Haven’t Noticed Read Post »
The New Owner Didn’t File the Patent. Here’s Who Actually Controls It.
Pfizer has sold Xtandi since it bought Medivation for $14 billion in 2016. Pfizer’s name is not on any of
The New Owner Didn’t File the Patent. Here’s Who Actually Controls It. Read Post »
Zero for Two: Why No Antibody-Drug Conjugate Has Ever Faced a Biosimilar
Kadcyla’s twelve-year reference exclusivity period ran out in February 2025. Adcetris lost its exclusivity years before that. Neither drug has
Zero for Two: Why No Antibody-Drug Conjugate Has Ever Faced a Biosimilar Read Post »
Platform Patents Were Supposed to Protect Gene Editing. Fourteen Years of CRISPR Litigation Say Otherwise.
On March 26, 2026, the Patent Trial and Appeal Board ruled, again, that the Broad Institute invented CRISPR-Cas9 gene editing
Stop Tracking Drug Patents. Start Tracking Who Controls Them.
On May 1, 2026, the company that made OxyContin stopped existing. Purdue Pharma dissolved and its pharmaceutical business restarted as
Stop Tracking Drug Patents. Start Tracking Who Controls Them. Read Post »
Google Patents Wasn’t Built for Pharma — Here’s What It Misses Every Time You Search a Drug Name
The Short Answer Google Patents is a free document index built for general-purpose prior art search. It has no connection
